Donald Hooker
Stock Analyst at Keybanc
(2.51)
# 2,335
Out of 4,761 analysts
82
Total ratings
55.95%
Success rate
9.22%
Average return
Main Sectors:
Stocks Rated by Donald Hooker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: Overweight | $180 → $100 | $11.51 | +768.81% | 18 | Feb 23, 2022 | |
| CRL Charles River Laboratories International | Maintains: Overweight | $450 → $390 | $163.02 | +139.23% | 5 | Feb 17, 2022 | |
| DGX Quest Diagnostics | Maintains: Overweight | $168 → $170 | $172.24 | -1.30% | 4 | Dec 13, 2021 | |
| IQV IQVIA Holdings | Maintains: Overweight | $270 → $290 | $191.04 | +51.80% | 4 | Nov 17, 2021 | |
| PHR Phreesia | Maintains: Overweight | $70 → $73 | $28.22 | +158.68% | 8 | Jul 12, 2021 | |
| RXRX Recursion Pharmaceuticals | Initiates: Overweight | $36 | $9.28 | +287.93% | 1 | May 11, 2021 | |
| AMWL American Well | Initiates: Sector Weight | n/a | $11.74 | - | 1 | Apr 16, 2021 | |
| VEEV Veeva Systems | Maintains: Overweight | $332 → $353 | $225.79 | +56.34% | 2 | Feb 17, 2021 | |
| HQY HealthEquity | Downgrades: Sector Weight | n/a | $108.60 | - | 11 | Dec 2, 2020 | |
| MMS Maximus | Maintains: Overweight | $80 → $84 | $66.00 | +27.27% | 2 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $10.43 | - | 8 | Jul 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $170 | $249.85 | -31.96% | 7 | Mar 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $201.39 | - | 6 | Sep 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $68 → $46 | $1.64 | +2,704.88% | 2 | Nov 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $18.61 | - | 1 | Oct 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $340.22 | - | 2 | Jul 10, 2017 |
Teladoc Health
Feb 23, 2022
Maintains: Overweight
Price Target: $180 → $100
Current: $11.51
Upside: +768.81%
Charles River Laboratories International
Feb 17, 2022
Maintains: Overweight
Price Target: $450 → $390
Current: $163.02
Upside: +139.23%
Quest Diagnostics
Dec 13, 2021
Maintains: Overweight
Price Target: $168 → $170
Current: $172.24
Upside: -1.30%
IQVIA Holdings
Nov 17, 2021
Maintains: Overweight
Price Target: $270 → $290
Current: $191.04
Upside: +51.80%
Phreesia
Jul 12, 2021
Maintains: Overweight
Price Target: $70 → $73
Current: $28.22
Upside: +158.68%
Recursion Pharmaceuticals
May 11, 2021
Initiates: Overweight
Price Target: $36
Current: $9.28
Upside: +287.93%
American Well
Apr 16, 2021
Initiates: Sector Weight
Price Target: n/a
Current: $11.74
Upside: -
Veeva Systems
Feb 17, 2021
Maintains: Overweight
Price Target: $332 → $353
Current: $225.79
Upside: +56.34%
HealthEquity
Dec 2, 2020
Downgrades: Sector Weight
Price Target: n/a
Current: $108.60
Upside: -
Maximus
Aug 7, 2020
Maintains: Overweight
Price Target: $80 → $84
Current: $66.00
Upside: +27.27%
Jul 6, 2020
Downgrades: Sector Weight
Price Target: n/a
Current: $10.43
Upside: -
Mar 30, 2020
Maintains: Overweight
Price Target: $212 → $170
Current: $249.85
Upside: -31.96%
Sep 23, 2019
Downgrades: Sector Weight
Price Target: n/a
Current: $201.39
Upside: -
Nov 13, 2017
Maintains: Overweight
Price Target: $68 → $46
Current: $1.64
Upside: +2,704.88%
Oct 24, 2017
Downgrades: Sector Weight
Price Target: n/a
Current: $18.61
Upside: -
Jul 10, 2017
Downgrades: Sector Weight
Price Target: n/a
Current: $340.22
Upside: -